venetoclax,quizartinib
roche,abbvie,daiichi sankyo
['quizartinib', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'venetoclax', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops)']
congress #asco22 | of presents results of a phase i/ii trial of quizartinib + decitabine + venetoclax in patients with flt3-itd #aml. n=28. median follow-up was 13 months. showed a crc rate of 82% with median os of 7.1 months. #leusm #medicalcongress 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm